Artwork

Content provided by Keyvan Koushan, MD, and FRCSC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Keyvan Koushan, MD, and FRCSC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

E23- CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD - Dr. Peter Kertes

15:10
 
Share
 

Manage episode 227837567 series 2416620
Content provided by Keyvan Koushan, MD, and FRCSC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Keyvan Koushan, MD, and FRCSC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. Peter Kertes discusses the publication of the first year results of the CANTREAT study that investigates monthly vs treat-and-extend dosing of ranibizumab for wet AMD.

Full reference:

Kertes, P. J., Galic, I. J., Greve, M., Williams, R. G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019). Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study. Ophthalmology. doi:10.1016/j.ophtha.2019.01.013

  continue reading

78 episodes

Artwork
iconShare
 
Manage episode 227837567 series 2416620
Content provided by Keyvan Koushan, MD, and FRCSC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Keyvan Koushan, MD, and FRCSC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. Peter Kertes discusses the publication of the first year results of the CANTREAT study that investigates monthly vs treat-and-extend dosing of ranibizumab for wet AMD.

Full reference:

Kertes, P. J., Galic, I. J., Greve, M., Williams, R. G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019). Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study. Ophthalmology. doi:10.1016/j.ophtha.2019.01.013

  continue reading

78 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide